Case report links mGluR1 antibodies to seizures in a cat
Bottom line
Version 1
A new case report in Frontiers in Veterinary Science describes what appears to be the first documented detection of metabotropic glutamate receptor 1, or mGluR1, antibodies in a cat with neurological disease. The patient was a 5.5-month-old domestic shorthair with recurrent seizures, episodic behavioral abnormalities including pica, and mild pelvic limb ataxia. Brain MRI and cerebrospinal fluid analysis were unremarkable, and infectious PCR testing on CSF was negative for feline coronavirus, Toxoplasma gondii, feline herpesvirus, and rustrela virus. Serum testing found an elevated mGluR1 antibody titer of 1:80, while CSF and tissue-based assays were negative, and the cat improved after antiseizure therapy was optimized, alongside a drop in serum antibody titer. (frontiersin.org)
Why it matters: For veterinarians, the report adds another possible immune-mediated mechanism to the differential list for young cats with seizures and behavior change, even when MRI and CSF are unrevealing. Feline autoimmune encephalitis has already been linked more often to antibodies such as LGI1 and CASPR2, and broader research groups are actively studying autoimmune seizure disorders in cats as a translational model for human disease. At the same time, the authors' finding needs cautious interpretation: in human medicine, serum-only mGluR1 positivity, especially without CSF confirmation, isn't considered sufficient on its own to establish anti-mGluR1 encephalitis. (frontiersin.org)
What to watch: Whether follow-up studies can confirm mGluR1 as a clinically meaningful feline autoantibody, ideally with species-specific assays, larger case series, and clearer treatment-response data. (frontiersin.org)
Key facts
- Study type
- Case report
- Journal
- Frontiers in Veterinary Science
- Patient
- 5.5-month-old domestic shorthair cat
- Clinical signs
- Recurrent seizures, pica, and mild pelvic limb ataxia
- Imaging and CSF
- Brain MRI and CSF analysis were unremarkable
- Infectious CSF testing
- Negative for feline coronavirus, Toxoplasma gondii, feline herpesvirus, and rustrela virus
- Antibody finding
- Serum mGluR1 titer 1:80; CSF and tissue-based assays were negative
- Outcome
- Cat improved after antiseizure therapy was optimized, with a drop in serum antibody titer
Version 2
A newly published feline case report may widen the autoimmune encephalitis conversation in companion animal neurology. Writing in Frontiers in Veterinary Science, investigators describe a 5.5-month-old domestic shorthair cat with recurrent epileptic seizures and episodic behavioral abnormalities that tested positive for serum metabotropic glutamate receptor 1, or mGluR1, antibodies, which the authors say is the first such detection reported in a cat. (frontiersin.org)
The case lands in a field that's been gaining momentum rather than starting from scratch. Autoimmune encephalitis is increasingly recognized in veterinary medicine, and in cats, the best-described antibody associations to date have primarily involved voltage-gated potassium channel complex targets such as LGI1 and CASPR2. Separate feline research and outreach efforts, including work highlighted by the Royal Veterinary College and BSAVA, have helped raise awareness that seizure clusters, focal orofacial events, and behavioral change can reflect immune-mediated brain disease in some cats. (frontiersin.org)
In this new report, the cat presented with seizures, pica, and mild pelvic limb ataxia, with forebrain localization on neurologic assessment. MRI of the brain and CSF analysis were unremarkable, and CSF infectious testing was negative for feline coronavirus, Toxoplasma gondii, feline herpesvirus, and rustrela virus. Neural antibody testing identified an elevated serum mGluR1 titer of 1:80, above the reported reference threshold of less than 1:20, while CSF and tissue-based assays were negative. Testing for other neuronal autoantibodies, including LGI1 and CASPR2, was also negative. After antiseizure therapy was optimized, the cat improved clinically, and the serum mGluR1 titer decreased in parallel. (frontiersin.org)
That pattern makes the case intriguing, but not definitive. In human neurology, mGluR1 autoimmunity is recognized, yet published reviews note that serum-only positivity, particularly at low titers and without CSF confirmation, can be difficult to interpret and may not be enough by itself to diagnose anti-mGluR1 encephalitis. The veterinary authors frame their findings carefully as a potential association rather than proof of causation, which is an important distinction for clinicians reading this as an early signal, not a settled diagnostic category. (frontiersin.org)
Industry and academic context also points to a broader diagnostic challenge: veterinary neurology is still relying heavily on adapted human antibody platforms while species-specific validation remains limited. A recent canine study in Frontiers in Veterinary Science reported mGluR1 antibodies in some dogs with suspected immune-mediated neurologic disease, but its authors also emphasized that current assays may miss relevant antibodies and that species-specific methods are needed to clarify clinical significance. That limitation likely applies here as well, especially for a single feline case with serum positivity only. (elib.tiho-hannover.de)
Why it matters: For veterinary professionals, this report reinforces two practical points. First, autoimmune disease should stay on the differential list for cats with seizures and behavioral abnormalities, even when MRI and CSF don't provide a clear answer. Second, antibody results need to be interpreted in context, alongside signalment, seizure phenotype, infectious rule-outs, imaging, CSF findings, and treatment response. The case may also matter to referral neurology and academic centers because it supports the idea that feline autoimmune seizure disorders could involve a wider antibody spectrum than previously recognized. (frontiersin.org)
What to watch: The next step is replication: more feline cases, better assay validation, and clearer correlation between antibody status, phenotype, CSF findings, and response to immunotherapy or antiseizure treatment. If additional reports emerge, mGluR1 testing could eventually become part of a more nuanced autoimmune epilepsy workup in cats, but for now, this looks more like a noteworthy first signal than a practice-changing standard. (frontiersin.org)